

Michael A Davies

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2862910/publications.pdf>

Version: 2024-02-01

199
papers

27,241
citations

13099

68
h-index

6654

156
g-index

212
all docs

212
docs citations

212
times ranked

32488
citing authors

#	ARTICLE	IF	CITATIONS
1	Cutaneous adverse events in 155 patients with metastatic melanoma consecutively treated with anti-CTLA4 and anti-PD1 combination immunotherapy: Incidence, management, and clinical benefit. <i>Cancer</i> , 2022, 128, 975-983.	4.1	12
2	Chemotherapy after immune checkpoint inhibitor failure in metastatic melanoma: a retrospective multicentre analysis. <i>European Journal of Cancer</i> , 2022, 162, 22-33.	2.8	28
3	Clinical Models to Define Response and Survival With Anti-PD-1 Antibodies Alone or Combined With Ipilimumab in Metastatic Melanoma. <i>Journal of Clinical Oncology</i> , 2022, 40, 1068-1080.	1.6	43
4	Distinct molecular and immune hallmarks of inflammatory arthritis induced by immune checkpoint inhibitors for cancer therapy. <i>Nature Communications</i> , 2022, 13, 1970.	12.8	34
5	Genomic Correlates of Outcome in Tumor-Infiltrating Lymphocyte Therapy for Metastatic Melanoma. <i>Clinical Cancer Research</i> , 2022, 28, 1911-1924.	7.0	3
6	Brain metastases: A Society for Neuro-Oncology (SNO) consensus review on current management and future directions. <i>Neuro-Oncology</i> , 2022, 24, 1613-1646.	1.2	39
7	PDXNet portal: patient-derived Xenograft model, data, workflow and tool discovery. <i>NAR Cancer</i> , 2022, 4, zcac014.	3.1	7
8	LFA-1 activation enriches tumor-specific T cells in a cold tumor model and synergizes with CTLA-4 blockade. <i>Journal of Clinical Investigation</i> , 2022, 132, .	8.2	14
9	Interleukin-6 blockade abrogates immunotherapy toxicity and promotes tumor immunity. <i>Cancer Cell</i> , 2022, 40, 509-523.e6.	16.8	115
10	Androgen receptor blockade promotes response to BRAF/MEK-targeted therapy. <i>Nature</i> , 2022, 606, 797-803.	27.8	54
11	Microenvironmental Landscape of Human Melanoma Brain Metastases in Response to Immune Checkpoint Inhibition. <i>Cancer Immunology Research</i> , 2022, 10, 996-1012.	3.4	18
12	Multi-modal molecular programs regulate melanoma cell state. <i>Nature Communications</i> , 2022, 13, .	12.8	9
13	Dissecting the treatment-naive ecosystem of human melanoma brain metastasis. <i>Cell</i> , 2022, 185, 2591-2608.e30.	28.9	62
14	Multi-omic molecular profiling reveals potentially targetable abnormalities shared across multiple histologies of brain metastasis. <i>Acta Neuropathologica</i> , 2021, 141, 303-321.	7.7	30
15	Tumor-infiltrating mast cells are associated with resistance to anti-PD-1 therapy. <i>Nature Communications</i> , 2021, 12, 346.	12.8	107
16	Conservation of copy number profiles during engraftment and passaging of patient-derived cancer xenografts. <i>Nature Genetics</i> , 2021, 53, 86-99.	21.4	118
17	iNOS Associates With Poor Survival in Melanoma: A Role for Nitric Oxide in the PI3K-AKT Pathway Stimulation and PTEN S-Nitrosylation. <i>Frontiers in Oncology</i> , 2021, 11, 631766.	2.8	10
18	Pathological response and survival with neoadjuvant therapy in melanoma: a pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC). <i>Nature Medicine</i> , 2021, 27, 301-309.	30.7	218

#	ARTICLE	IF	CITATIONS
19	Targeted Therapy Given after Anti-PD-1 Leads to Prolonged Responses in Mouse Melanoma Models through Sustained Antitumor Immunity. <i>Cancer Immunology Research</i> , 2021, 9, 554-567.	3.4	15
20	Circulating tumour DNA in patients with advanced melanoma treated with dabrafenib or dabrafenib plus trametinib: a clinical validation study. <i>Lancet Oncology</i> , The, 2021, 22, 370-380.	10.7	57
21	Tilsotolimod with Ipilimumab Drives Tumor Responses in Anti-PD-1 Refractory Melanoma. <i>Cancer Discovery</i> , 2021, 11, 1996-2013.	9.4	32
22	The efficacy of anti-programmed cell death protein 1 therapy among patients with metastatic acral and metastatic mucosal melanoma. <i>Cancer Medicine</i> , 2021, 10, 2293-2299.	2.8	15
23	High sensitivity sanger sequencing detection of BRAF mutations in metastatic melanoma FFPE tissue specimens. <i>Scientific Reports</i> , 2021, 11, 9043.	3.3	13
24	Nodal Recurrence is a Primary Driver of Early Relapse for Patients with Sentinel Lymph Node-Positive Melanoma in the Modern Therapeutic Era. <i>Annals of Surgical Oncology</i> , 2021, 28, 3480-3489.	1.5	7
25	Efficacy and Safety of Trametinib in Non-V600 BRAF Mutant Melanoma: A Phase II Study. <i>Oncologist</i> , 2021, 26, 731-e1498.	3.7	20
26	Randomized phase II trial of lymphodepletion plus adoptive cell transfer of tumor-infiltrating lymphocytes, with or without dendritic cell vaccination, in patients with metastatic melanoma. , 2021, 9, e002449.		16
27	Re-thinking therapeutic development for CNS metastatic disease. <i>Experimental Dermatology</i> , 2021, , .	2.9	1
28	Neoantigen vaccination induces clinical and immunologic responses in non-small cell lung cancer patients harboring EGFR mutations. , 2021, 9, e002531.		24
29	Gut microbiota signatures are associated with toxicity to combined CTLA-4 and PD-1 blockade. <i>Nature Medicine</i> , 2021, 27, 1432-1441.	30.7	216
30	Comprehensive characterization of 536 patient-derived xenograft models prioritizes candidates for targeted treatment. <i>Nature Communications</i> , 2021, 12, 5086.	12.8	58
31	High-dose irradiation in combination with non-ablative low-dose radiation to treat metastatic disease after progression on immunotherapy: Results of a phase II trial. <i>Radiotherapy and Oncology</i> , 2021, 162, 60-67.	0.6	45
32	Clinical, molecular, metabolic, and immune features associated with oxidative phosphorylation in melanoma brain metastases. <i>Neuro-Oncology Advances</i> , 2021, 3, vdaa177.	0.7	12
33	Identification of MicroRNA-mRNA Networks in Melanoma and Their Association with PD-1 Checkpoint Blockade Outcomes. <i>Cancers</i> , 2021, 13, 5301.	3.7	7
34	Short-term treatment with multi-drug regimens combining BRAF/MEK-targeted therapy and immunotherapy results in durable responses in BRAF-mutated melanoma. <i>Oncolmmunology</i> , 2021, 10, 1992880.	4.6	7
35	Targeted therapy strategies for melanoma brain metastasis. <i>Neuro-Oncology Advances</i> , 2021, 3, v75-v85.	0.7	3
36	Dietary fiber and probiotics influence the gut microbiome and melanoma immunotherapy response. <i>Science</i> , 2021, 374, 1632-1640.	12.6	369

#	ARTICLE	IF	CITATIONS
37	Prognostic model for patient survival in primary anorectal mucosal melanoma: stage at presentation determines relevance of histopathologic features. <i>Modern Pathology</i> , 2020, 33, 496-513.	5.5	19
38	Intracranial antitumor activity with encorafenib plus binimetinib in patients with melanoma brain metastases: A case series. <i>Cancer</i> , 2020, 126, 523-530.	4.1	43
39	Targeting BRD/BET proteins inhibits adaptive kinome upregulation and enhances the effects of BRAF/MEK inhibitors in melanoma. <i>British Journal of Cancer</i> , 2020, 122, 789-800.	6.4	15
40	Inhibiting insulin and mTOR signaling by afatinib and crizotinib combination fosters broad cytotoxic effects in cutaneous malignant melanoma. <i>Cell Death and Disease</i> , 2020, 11, 882.	6.3	10
41	Histopathological features of complete pathological response predict recurrence-free survival following neoadjuvant targeted therapy for metastatic melanoma. <i>Annals of Oncology</i> , 2020, 31, 1569-1579.	1.2	18
42	Molecular and immunological associations of elevated serum lactate dehydrogenase in metastatic melanoma patients: A fresh look at an old biomarker. <i>Cancer Medicine</i> , 2020, 9, 8650-8661.	2.8	11
43	Osteonecrosis of the jaw induced by treatment with anti-PD-1 immunotherapy: a case report. <i>Immunotherapy</i> , 2020, 12, 1213-1219.	2.0	6
44	Melanoma Evolves Complete Immunotherapy Resistance through the Acquisition of a Hypermetabolic Phenotype. <i>Cancer Immunology Research</i> , 2020, 8, 1365-1380.	3.4	37
45	Large-Scale Characterization of Drug Responses of Clinically Relevant Proteins in Cancer Cell Lines. <i>Cancer Cell</i> , 2020, 38, 829-843.e4.	16.8	40
46	Targeting PHGDH Upregulation Reduces Glutathione Levels and Resensitizes Resistant NRAS-Mutant Melanoma to MAPK Kinase Inhibition. <i>Journal of Investigative Dermatology</i> , 2020, 140, 2242-2252.e7.	0.7	23
47	Metabolic Adaptations to MEK and CDK4/6 Cotargeting in Uveal Melanoma. <i>Molecular Cancer Therapeutics</i> , 2020, 19, 1719-1726.	4.1	22
48	Limited Environmental Serine and Glycine Confer Brain Metastasis Sensitivity to PHGDH Inhibition. <i>Cancer Discovery</i> , 2020, 10, 1352-1373.	9.4	145
49	Combination treatment with radiotherapy and a novel oxidative phosphorylation inhibitor overcomes PD-1 resistance and enhances antitumor immunity. , 2020, 8, e000289.		51
50	Is It Safe to Stop Anti-“PD-1 Immunotherapy in Patients With Metastatic Melanoma Who Achieve a Complete Response?. <i>Journal of Clinical Oncology</i> , 2020, 38, 1645-1647.	1.6	10
51	FOXD3 Regulates VISTA Expression in Melanoma. <i>Cell Reports</i> , 2020, 30, 510-524.e6.	6.4	42
52	B cells and tertiary lymphoid structures promote immunotherapy response. <i>Nature</i> , 2020, 577, 549-555.	27.8	1,421
53	Cumulative Incidence and Predictors of CNS Metastasis for Patients With American Joint Committee on Cancer 8th Edition Stage III Melanoma. <i>Journal of Clinical Oncology</i> , 2020, 38, 1429-1441.	1.6	23
54	Leptomeningeal disease in melanoma patients: An update to treatment, challenges, and future directions. <i>Pigment Cell and Melanoma Research</i> , 2020, 33, 527-541.	3.3	36

#	ARTICLE	IF	CITATIONS
55	Upregulation of cell surface GD3 ganglioside phenotype is associated with human melanoma brain metastasis. <i>Molecular Oncology</i> , 2020, 14, 1760-1778.	4.6	27
56	Spatially resolved analyses link genomic and immune diversity and reveal unfavorable neutrophil activation in melanoma. <i>Nature Communications</i> , 2020, 11, 1839.	12.8	15
57	Circulating Tumor Cells and Early Relapse in Node-positive Melanoma. <i>Clinical Cancer Research</i> , 2020, 26, 1886-1895.	7.0	42
58	EXTH-06. INTEGRATED MOLECULAR PROFILING REVEALS TARGETABLE MOLECULAR ABNORMALITIES SHARED ACROSS MULTIPLE HISTOLOGIES OF BRAIN METASTASIS. <i>Neuro-Oncology</i> , 2020, 22, ii87-ii88.	1.2	0
59	Incidence, patterns of progression, and outcomes of preexisting and newly discovered brain metastases during treatment with anti-“PD” in patients with metastatic melanoma. <i>Cancer</i> , 2019, 125, 4193-4202.	4.1	9
60	Anti-OX40 Antibody Directly Enhances The Function of Tumor-Reactive CD8+ T Cells and Synergizes with PI3K ² Inhibition in PTEN Loss Melanoma. <i>Clinical Cancer Research</i> , 2019, 25, 6406-6416.	7.0	35
61	Neoadjuvant systemic therapy in melanoma: recommendations of the International Neoadjuvant Melanoma Consortium. <i>Lancet Oncology</i> , The, 2019, 20, e378-e389.	10.7	155
62	<i>In Vivo</i> ERK1/2 Reporter Predictively Models Response and Resistance to Combined BRAF and MEK Inhibitors in Melanoma. <i>Molecular Cancer Therapeutics</i> , 2019, 18, 1637-1648.	4.1	14
63	Regulation of PRMT5-“MDM4 axis is critical in the response to CDK4/6 inhibitors in melanoma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 17990-18000.	7.1	81
64	A Novel Mitochondrial Inhibitor Blocks MAPK Pathway and Overcomes MAPK Inhibitor Resistance in Melanoma. <i>Clinical Cancer Research</i> , 2019, 25, 6429-6442.	7.0	61
65	AKT1E17K Activates Focal Adhesion Kinase and Promotes Melanoma Brain Metastasis. <i>Molecular Cancer Research</i> , 2019, 17, 1787-1800.	3.4	46
66	Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma. <i>New England Journal of Medicine</i> , 2019, 381, 626-636.	27.0	909
67	Modern Management of Central Nervous System Metastases in the Era of Targeted Therapy and Immune Oncology. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2019, 39, e59-e69.	3.8	8
68	Reply to A. Shinde et al. <i>Journal of Clinical Oncology</i> , 2019, 37, 1031-1032.	1.6	0
69	Predictors of survival in metastatic melanoma patients with leptomeningeal disease (LMD). <i>Journal of Neuro-Oncology</i> , 2019, 142, 499-509.	2.9	33
70	Molecular Profiling Reveals Unique Immune and Metabolic Features of Melanoma Brain Metastases. <i>Cancer Discovery</i> , 2019, 9, 628-645.	9.4	231
71	Mechanism-Specific Pharmacodynamics of a Novel Complex-I Inhibitor Quantified by Imaging Reversal of Consumptive Hypoxia with [18F]FAZA PET In Vivo. <i>Cells</i> , 2019, 8, 1487.	4.1	20
72	Immune checkpoint inhibitor related myasthenia gravis: single center experience and systematic review of the literature. , 2019, 7, 319.		164

#	ARTICLE	IF	CITATIONS
73	Melanoma central nervous system metastases: An update to approaches, challenges, and opportunities. <i>Pigment Cell and Melanoma Research</i> , 2019, 32, 458-469.	3.3	31
74	Case Report: Sarcoidosis mimicking head and neck cancer progression. <i>F1000Research</i> , 2019, 8, 215.	1.6	2
75	<i>In Vivo</i> E2F Reporting Reveals Efficacious Schedules of MEK1/2+CDK4/6 Targeting and mTOR+S6 Resistance Mechanisms. <i>Cancer Discovery</i> , 2018, 8, 568-581.	9.4	62
76	The RNA-binding Protein MEX3B Mediates Resistance to Cancer Immunotherapy by Downregulating HLA-A Expression. <i>Clinical Cancer Research</i> , 2018, 24, 3366-3376.	7.0	73
77	A Preexisting Rare PIK3CA E545K Subpopulation Confers Clinical Resistance to MEK plus CDK4/6 Inhibition in NRAS Melanoma and Is Dependent on S6K1 Signaling. <i>Cancer Discovery</i> , 2018, 8, 556-567.	9.4	55
78	Estrogen returns to the stage in melanoma. <i>Pigment Cell and Melanoma Research</i> , 2018, 31, 554-555.	3.3	4
79	Increased Tumor Glycolysis Characterizes Immune Resistance to Adoptive T Cell Therapy. <i>Cell Metabolism</i> , 2018, 27, 977-987.e4.	16.2	398
80	Retrospective review of metastatic melanoma patients with leptomeningeal disease treated with intrathecal interleukin-2. <i>ESMO Open</i> , 2018, 3, e000283.	4.5	45
81	Neoadjuvant plus adjuvant dabrafenib and trametinib versus standard of care in patients with high-risk, surgically resectable melanoma: a single-centre, open-label, randomised, phase 2 trial. <i>Lancet Oncology</i> , 2018, 19, 181-193.	10.7	233
82	Association of body-mass index and outcomes in patients with metastatic melanoma treated with targeted therapy, immunotherapy, or chemotherapy: a retrospective, multicohort analysis. <i>Lancet Oncology</i> , 2018, 19, 310-322.	10.7	486
83	Metabolic strategies of melanoma cells: Mechanisms, interactions with the tumor microenvironment, and therapeutic implications. <i>Pigment Cell and Melanoma Research</i> , 2018, 31, 11-30.	3.3	149
84	Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients. <i>Science</i> , 2018, 359, 97-103.	12.6	3,126
85	First-in-human trial of the PI3K-selective inhibitor SAR260301 in patients with advanced solid tumors. <i>Cancer</i> , 2018, 124, 315-324.	4.1	29
86	Moving treatments earlier to move further forwards. <i>Nature Reviews Clinical Oncology</i> , 2018, 15, 75-76.	27.6	7
87	Melanoma brain metastases harboring BRAF V600K or NRAS mutations are associated with an increased local failure rate following conventional therapy. <i>Journal of Neuro-Oncology</i> , 2018, 137, 67-75.	2.9	17
88	Response and Resistance to Paradox-Breaking BRAF Inhibitor in Melanomas <i>In Vivo</i> and <i>Ex Vivo</i> . <i>Molecular Cancer Therapeutics</i> , 2018, 17, 84-95.	4.1	22
89	Biological Validation of RNA Sequencing Data From Formalin-Fixed Paraffin-Embedded Primary Melanomas. <i>JCO Precision Oncology</i> , 2018, 2018, 1-19.	3.0	19
90	Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma. <i>Nature Medicine</i> , 2018, 24, 1649-1654.	30.7	592

#	ARTICLE	IF	CITATIONS
91	Role of Elevated <i>PHIP</i> Copy Number as a Prognostic and Progression Marker for Cutaneous Melanoma. <i>Clinical Cancer Research</i> , 2018, 24, 4119-4125.	7.0	11
92	Prospective Analysis of Adoptive TIL Therapy in Patients with Metastatic Melanoma: Response, Impact of Anti-CTLA4, and Biomarkers to Predict Clinical Outcome. <i>Clinical Cancer Research</i> , 2018, 24, 4416-4428.	7.0	89
93	Pathological assessment of resection specimens after neoadjuvant therapy for metastatic melanoma. <i>Annals of Oncology</i> , 2018, 29, 1861-1868.	1.2	135
94	Targeting USP7 Identifies a Metastasis-Competent State within Bone Marrow Resident Melanoma CTCs. <i>Cancer Research</i> , 2018, 78, 5349-5362.	0.9	36
95	ALK Fusion Partners Impact Response to ALK Inhibition: Differential Effects on Sensitivity, Cellular Phenotypes, and Biochemical Properties. <i>Molecular Cancer Research</i> , 2018, 16, 1724-1736.	3.4	74
96	Body-mass index and metastatic melanoma outcomes – Authors' reply. <i>Lancet Oncology</i> , The, 2018, 19, e227-e228.	10.7	3
97	ErbB3 Targeting Enhances the Effects of MEK Inhibitor in Wild-Type BRAF/NRAS Melanoma. <i>Cancer Research</i> , 2018, 78, 5680-5693.	0.9	19
98	Sex as a predictor of response to cancer immunotherapy. <i>Lancet Oncology</i> , The, 2018, 19, e376.	10.7	8
99	Evaluating Circulating Tumor DNA From the Cerebrospinal Fluid of Patients With Melanoma and Leptomeningeal Disease. <i>Journal of Neuropathology and Experimental Neurology</i> , 2018, 77, 628-635.	1.7	57
100	Profiles of brain metastases: Prioritization of therapeutic targets. <i>International Journal of Cancer</i> , 2018, 143, 3019-3026.	5.1	31
101	Co-targeting HGF/cMET Signaling with MEK Inhibitors in Metastatic Uveal Melanoma. <i>Molecular Cancer Therapeutics</i> , 2017, 16, 516-528.	4.1	55
102	Integrated molecular analysis of tumor biopsies on sequential CTLA-4 and PD-1 blockade reveals markers of response and resistance. <i>Science Translational Medicine</i> , 2017, 9, .	12.4	689
103	Characterization of Human Cancer Cell Lines by Reverse-phase Protein Arrays. <i>Cancer Cell</i> , 2017, 31, 225-239.	16.8	190
104	Epigenetic Regulation of KPC1 Ubiquitin Ligase Affects the NF- κ B Pathway in Melanoma. <i>Clinical Cancer Research</i> , 2017, 23, 4831-4842.	7.0	33
105	Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study. <i>Annals of Oncology</i> , 2017, 28, 1631-1639.	1.2	549
106	Systematic Epigenomic Analysis Reveals Chromatin States Associated with Melanoma Progression. <i>Cell Reports</i> , 2017, 19, 875-889.	6.4	78
107	Association between Body Mass Index, C-Reactive Protein Levels, and Melanoma Patient Outcomes. <i>Journal of Investigative Dermatology</i> , 2017, 137, 1792-1795.	0.7	40
108	Biomarker Accessible and Chemically Addressable Mechanistic Subtypes of BRAF Melanoma. <i>Cancer Discovery</i> , 2017, 7, 832-851.	9.4	49

#	ARTICLE	IF	CITATIONS
109	Clinicopathological features and clinical outcomes associated with TP53 and BRAF ^N mutations in cutaneous melanoma patients. <i>Cancer</i> , 2017, 123, 1372-1381.	4.1	36
110	Three-year pooled analysis of factors associated with clinical outcomes across dabrafenib and trametinib combination therapy phase 3 randomised trials. <i>European Journal of Cancer</i> , 2017, 82, 45-55.	2.8	160
111	Dabrafenib plus trametinib in patients with BRAFV600-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial. <i>Lancet Oncology</i> , The, 2017, 18, 863-873.	10.7	561
112	Genomic and immune heterogeneity are associated with differential responses to therapy in melanoma. <i>Npj Genomic Medicine</i> , 2017, 2, .	3.8	120
113	Thrombocytopenia in patients with melanoma receiving immune checkpoint inhibitor therapy. , 2017, 5, 8.		111
114	Tumor Thickness and Mitotic Rate Robustly Predict Melanoma-Specific Survival in Patients with Primary Vulvar Melanoma: A Retrospective Review of 100 Cases. <i>Clinical Cancer Research</i> , 2017, 23, 2093-2104.	7.0	48
115	Erythema nodosum-like panniculitis mimicking disease recurrence: A novel toxicity from immune checkpoint blockade therapy—Report of 2 patients. <i>Journal of Cutaneous Pathology</i> , 2017, 44, 1080-1086.	1.3	48
116	Stereotactic radiosurgery of early melanoma brain metastases after initiation of anti-CTLA-4 treatment is associated with improved intracranial control. <i>Radiotherapy and Oncology</i> , 2017, 125, 80-88.	0.6	58
117	Tumor-associated B-cells induce tumor heterogeneity and therapy resistance. <i>Nature Communications</i> , 2017, 8, 607.	12.8	109
118	Comparative immunologic characterization of autoimmune giant cell myocarditis with ipilimumab. <i>Oncolmmunology</i> , 2017, 6, e1361097.	4.6	50
119	Genetic and Genomic Characterization of 462 Melanoma Patient-Derived Xenografts, Tumor Biopsies, and Cell Lines. <i>Cell Reports</i> , 2017, 21, 1936-1952.	6.4	72
120	Harnessing BET Inhibitor Sensitivity Reveals AMIGO2 as a Melanoma Survival Gene. <i>Molecular Cell</i> , 2017, 68, 731-744.e9.	9.7	90
121	A Comprehensive Patient-Derived Xenograft Collection Representing the Heterogeneity of Melanoma. <i>Cell Reports</i> , 2017, 21, 1953-1967.	6.4	117
122	Assessment of Compliance With Texas Legislation Banning Indoor UV Tanning by Minors. <i>JAMA Dermatology</i> , 2017, 153, 228.	4.1	10
123	Primary medical therapy for BRAFV600E-mutant melanoma brain metastases—is this good enough? —Authors' reply. <i>Lancet Oncology</i> , The, 2017, 18, e509.	10.7	3
124	COMBI-MB: A phase II study of combination dabrafenib (D) and trametinib (T) in patients (pts) with BRAF ^{V600} mutant (mut) melanoma brain metastases (MBM).. <i>Journal of Clinical Oncology</i> , 2017, 35, 9506-9506.	1.6	10
125	Targeting mitochondrial biogenesis to overcome drug resistance to MAPK inhibitors. <i>Journal of Clinical Investigation</i> , 2016, 126, 1834-1856.	8.2	219
126	Next-generation sequencing identifies high frequency of mutations in potentially clinically actionable genes in sebaceous carcinoma. <i>Journal of Pathology</i> , 2016, 240, 84-95.	4.5	63

#	ARTICLE	IF	CITATIONS
127	MIG6 Is MEK Regulated and Affects EGF-Induced Migration in Mutant NRAS Melanoma. <i>Journal of Investigative Dermatology</i> , 2016, 136, 453-463.	0.7	13
128	Clinical, Molecular, and Immune Analysis of Dabrafenib-Trametinib Combination Treatment for BRAF Inhibitor-Resistant Refractory Metastatic Melanoma. <i>JAMA Oncology</i> , 2016, 2, 1056.	7.1	41
129	An <i>In Vivo</i> Reporter to Quantitatively and Temporally Analyze the Effects of CDK4/6 Inhibitor-Based Therapies in Melanoma. <i>Cancer Research</i> , 2016, 76, 5455-5466.	0.9	24
130	The state of melanoma: challenges and opportunities. <i>Pigment Cell and Melanoma Research</i> , 2016, 29, 404-416.	3.3	77
131	Melanoma central nervous system metastases: current approaches, challenges, and opportunities. <i>Pigment Cell and Melanoma Research</i> , 2016, 29, 627-642.	3.3	102
132	Factors predictive of response, disease progression, and overall survival after dabrafenib and trametinib combination treatment: a pooled analysis of individual patient data from randomised trials. <i>Lancet Oncology</i> , The, 2016, 17, 1743-1754.	10.7	266
133	Novel algorithmic approach predicts tumor mutation load and correlates with immunotherapy clinical outcomes using a defined gene mutation set. <i>BMC Medicine</i> , 2016, 14, 168.	5.5	106
134	Somatic Copy Number Alterations at Oncogenic Loci Show Diverse Correlations with Gene Expression. <i>Scientific Reports</i> , 2016, 6, 19649.	3.3	15
135	How Do We Make Clinical Molecular Testing for Cancer Standard of Care for Pathology Departments?. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2016, 14, 787-792.	4.9	4
136	Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade. <i>Cancer Discovery</i> , 2016, 6, 827-837.	9.4	785
137	Loss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy. <i>Cancer Discovery</i> , 2016, 6, 202-216.	9.4	1,158
138	Distinct clinical patterns and immune infiltrates are observed at time of progression on targeted therapy versus immune checkpoint blockade for melanoma. <i>Oncotarget</i> , 2016, 5, e1136044.	4.6	55
139	Inflammatory Marker Testing Identifies CD74 Expression in Melanoma Tumor Cells, and Its Expression Associates with Favorable Survival for Stage III Melanoma. <i>Clinical Cancer Research</i> , 2016, 22, 3016-3024.	7.0	39
140	Gas6/Axl is the sensor of arginine-auxotrophic response in targeted chemotherapy with arginine-depleting agents. <i>Oncogene</i> , 2016, 35, 1632-1642.	5.9	19
141	IMCT-07 THERAPEUTIC OUTCOMES OF INTRATHECAL INTERLEUKIN-2 IN METASTATIC MELANOMA PATIENTS WITH LEPTOMENINGEAL DISEASE (LMD). <i>Neuro-Oncology</i> , 2015, 17, v108.3-v108.	1.2	5
142	Role and complexity of next-generation sequencing in melanoma. <i>Cancer Cytopathology</i> , 2015, 123, 329-330.	2.4	0
143	Converting biology into clinical benefit: lessons learned from BRAF inhibitors. <i>Melanoma Management</i> , 2015, 2, 241-254.	0.5	10
144	RAC1 P29S regulates PD-L1 expression in melanoma. <i>Pigment Cell and Melanoma Research</i> , 2015, 28, 590-598.	3.3	69

#	ARTICLE	IF	CITATIONS
145	Use of clinical next-generation sequencing to identify melanomas harboring <i>SMARCB1</i> mutations. <i>Journal of Cutaneous Pathology</i> , 2015, 42, 308-317.	1.3	11
146	AKT1 Activation Promotes Development of Melanoma Metastases. <i>Cell Reports</i> , 2015, 13, 898-905.	6.4	124
147	Clinical Actionability Enhanced through Deep Targeted Sequencing of Solid Tumors. <i>Clinical Chemistry</i> , 2015, 61, 544-553.	3.2	85
148	mTORC1 Activation Blocks <i>Braf</i> V600E-Induced Growth Arrest but Is Insufficient for Melanoma Formation. <i>Cancer Cell</i> , 2015, 27, 41-56.	16.8	106
149	PKD1 and SGK3 Contribute to the Growth of BRAF-Mutant Melanomas and Are Potential Therapeutic Targets. <i>Cancer Research</i> , 2015, 75, 1399-1412.	0.9	50
150	Hotspot Mutation Panel Testing Reveals Clonal Evolution in a Study of 265 Paired Primary and Metastatic Tumors. <i>Clinical Cancer Research</i> , 2015, 21, 2644-2651.	7.0	70
151	<i>ErbB3</i> – <i>ErbB2</i> Complexes as a Therapeutic Target in a Subset of Wild-type BRAF/NRAS Cutaneous Melanomas. <i>Cancer Research</i> , 2015, 75, 3554-3567.	0.9	18
152	BRAFV600E Co-opts a Conserved MHC Class I Internalization Pathway to Diminish Antigen Presentation and CD8+ T-cell Recognition of Melanoma. <i>Cancer Immunology Research</i> , 2015, 3, 602-609.	3.4	133
153	A Decision Support Framework for Genomically Informed Investigational Cancer Therapy. <i>Journal of the National Cancer Institute</i> , 2015, 107, .	6.3	168
154	BRAF in early stage melanoma: rationale for testing and treatment?. <i>British Journal of Dermatology</i> , 2015, 173, 9-10.	1.5	0
155	Intrathecal Administration of Tumor-Infiltrating Lymphocytes Is Well Tolerated in a Patient with Leptomeningeal Disease from Metastatic Melanoma: A Case Report. <i>Cancer Immunology Research</i> , 2015, 3, 1201-1206.	3.4	29
156	Utility of BRAF V600E Immunohistochemistry Expression Pattern as a Surrogate of BRAF Mutation Status in 154 Patients with Advanced Melanoma. <i>Human Pathology</i> , 2015, 46, 1101-1110.	2.0	43
157	SBI-0640756 Attenuates the Growth of Clinically Unresponsive Melanomas by Disrupting the eIF4F Translation Initiation Complex. <i>Cancer Research</i> , 2015, 75, 5211-5218.	0.9	28
158	Development of a robust classifier for quality control of reverse-phase protein arrays. <i>Bioinformatics</i> , 2015, 31, 912-918.	4.1	43
159	Beyond BRAF V600 : Clinical Mutation Panel Testing by Next-Generation Sequencing in Advanced Melanoma. <i>Journal of Investigative Dermatology</i> , 2015, 135, 508-515.	0.7	138
160	Inhibition of mTORC1/2 Overcomes Resistance to MAPK Pathway Inhibitors Mediated by PGC1 α and Oxidative Phosphorylation in Melanoma. <i>Cancer Research</i> , 2014, 74, 7037-7047.	0.9	161
161	Function-Blocking ERBB3 Antibody Inhibits the Adaptive Response to RAF Inhibitor. <i>Cancer Research</i> , 2014, 74, 4122-4132.	0.9	45
162	Finding the Right Balance of BRAF Inhibition in Melanoma. <i>Cancer Discovery</i> , 2014, 4, 510-512.	9.4	3

#	ARTICLE	IF	CITATIONS
163	Somatic Mutations in MAP3K5 Attenuate Its Proapoptotic Function in Melanoma through Increased Binding to Thioredoxin. <i>Journal of Investigative Dermatology</i> , 2014, 134, 452-460.	0.7	20
164	Emerging insights into resistance to BRAF inhibitors in melanoma. <i>Biochemical Pharmacology</i> , 2014, 87, 381-389.	4.4	70
165	Molecular Profiling of Patient-Matched Brain and Extracranial Melanoma Metastases Implicates the PI3K Pathway as a Therapeutic Target. <i>Clinical Cancer Research</i> , 2014, 20, 5537-5546.	7.0	169
166	Complete Loss of PTEN Protein Expression Correlates with Shorter Time to Brain Metastasis and Survival in Stage IIIB/C Melanoma Patients with <i>BRAF</i> V600 Mutations. <i>Clinical Cancer Research</i> , 2014, 20, 5527-5536.	7.0	145
167	Targeted Therapy Resistance Mechanisms and Therapeutic Implications in Melanoma. <i>Hematology/Oncology Clinics of North America</i> , 2014, 28, 523-536.	2.2	23
168	Targeted therapy for melanoma: rational combinatorial approaches. <i>Oncogene</i> , 2014, 33, 1-9.	5.9	85
169	Genotyping of cutaneous melanoma. <i>Chinese Clinical Oncology</i> , 2014, 3, 27.	1.2	17
170	Clinical characteristics and outcomes with specific <i>BRAF</i> and <i>NRAS</i> mutations in patients with metastatic melanoma. <i>Cancer</i> , 2013, 119, 3821-3829.	4.1	87
171	Navigating the Therapeutic Complexity of PI3K Pathway Inhibition in Melanoma. <i>Clinical Cancer Research</i> , 2013, 19, 5310-5319.	7.0	78
172	BRAF Inhibition Increases Tumor Infiltration by T cells and Enhances the Antitumor Activity of Adoptive Immunotherapy in Mice. <i>Clinical Cancer Research</i> , 2013, 19, 393-403.	7.0	336
173	Targeted Therapy for Brain Metastases. <i>Advances in Pharmacology</i> , 2012, 65, 109-142.	2.0	11
174	The Role of the PI3K-AKT Pathway in Melanoma. <i>Cancer Journal (Sudbury, Mass)</i> , 2012, 18, 142-147.	2.0	197
175	Oncogenic BRAF(V600E) Promotes Stromal Cell-Mediated Immunosuppression Via Induction of Interleukin-1 in Melanoma. <i>Clinical Cancer Research</i> , 2012, 18, 5329-5340.	7.0	266
176	Phase I Study of the Combination of Sorafenib and Temsirolimus in Patients with Metastatic Melanoma. <i>Clinical Cancer Research</i> , 2012, 18, 1120-1128.	7.0	57
177	Role and therapeutic potential of PI3K-mTOR signaling in de novo resistance to BRAF inhibition. <i>Pigment Cell and Melanoma Research</i> , 2012, 25, 248-258.	3.3	98
178	A Phase I Multi-Institutional Study of Systemic Sorafenib in Conjunction with Regional Melphalan for In-Transit Melanoma of the Extremity. <i>Annals of Surgical Oncology</i> , 2012, 19, 3896-3905.	1.5	22
179	Specific Lymphocyte Subsets Predict Response to Adoptive Cell Therapy Using Expanded Autologous Tumor-Infiltrating Lymphocytes in Metastatic Melanoma Patients. <i>Clinical Cancer Research</i> , 2012, 18, 6758-6770.	7.0	345
180	New Strategies in Melanoma: Molecular Testing in Advanced Disease. <i>Clinical Cancer Research</i> , 2012, 18, 1195-1200.	7.0	61

#	ARTICLE	IF	CITATIONS
181	Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial. <i>Lancet Oncology</i> , The, 2012, 13, 1087-1095.	10.7	841
182	A Landscape of Driver Mutations in Melanoma. <i>Cell</i> , 2012, 150, 251-263.	28.9	2,247
183	<i>NRAS</i> mutation status is an independent prognostic factor in metastatic melanoma. <i>Cancer</i> , 2012, 118, 4014-4023.	4.1	589
184	Targeted Therapy for Melanoma: A Primer. <i>Surgical Oncology Clinics of North America</i> , 2011, 20, 165-180.	1.5	25
185	Regulation, Role, and Targeting of Akt in Cancer. <i>Journal of Clinical Oncology</i> , 2011, 29, 4715-4717.	1.6	48
186	Prognostic factors for survival in melanoma patients with brain metastases. <i>Cancer</i> , 2011, 117, 1687-1696.	4.1	433
187	Analysis of the genome to personalize therapy for melanoma. <i>Oncogene</i> , 2010, 29, 5545-5555.	5.9	125
188	Basal and Treatment-Induced Activation of AKT Mediates Resistance to Cell Death by AZD6244 (ARRY-142886) in <i>Braf</i> -Mutant Human Cutaneous Melanoma Cells. <i>Cancer Research</i> , 2010, 70, 8736-8747.	0.9	222
189	Phosphatidylinositol-3-Kinase as a Therapeutic Target in Melanoma. <i>Clinical Cancer Research</i> , 2009, 15, 3029-3036.	7.0	59
190	Integrated Molecular and Clinical Analysis of AKT Activation in Metastatic Melanoma. <i>Clinical Cancer Research</i> , 2009, 15, 7538-7546.	7.0	221
191	A novel AKT3 mutation in melanoma tumours and cell lines. <i>British Journal of Cancer</i> , 2008, 99, 1265-1268.	6.4	237
192	Point mutations of protein kinases and individualised cancer therapy. <i>Expert Opinion on Pharmacotherapy</i> , 2006, 7, 2243-2261.	1.8	27
193	Motif analysis of the tumor suppressor gene MMAC/PTEN identifies tyrosines critical for tumor suppression and lipid phosphatase activity. <i>Oncogene</i> , 2002, 21, 2357-2364.	5.9	21
194	Suppression of matrix metalloproteinase-2 gene expression and invasion in human glioma cells by MMAC/PTEN. <i>Oncogene</i> , 2001, 20, 6669-6678.	5.9	107
195	Differential Effects of Phosphatidylinositol-3/Akt-Kinase Inhibition on Apoptotic Sensitization to Cytokines in LNCaP and PC-3 Prostate Cancer Cells. <i>Journal of Interferon and Cytokine Research</i> , 2001, 21, 313-322.	1.2	21
196	MMAC1/PTEN inhibits cell growth and induces chemosensitivity to doxorubicin in human bladder cancer cells. <i>Oncogene</i> , 2000, 19, 5406-5412.	5.9	94
197	The PTEN/MMAC1/TEP tumor suppressor gene decreases cell growth and induces apoptosis and anoikis in breast cancer cells. <i>Oncogene</i> , 1999, 18, 7034-7045.	5.9	288
198	Regulation of Akt/PKB activity, cellular growth, and apoptosis in prostate carcinoma cells by MMAC/PTEN. <i>Cancer Research</i> , 1999, 59, 2551-6.	0.9	205

#	ARTICLE	IF	CITATIONS
199	Adenoviral transgene expression of MMAC/PTEN in human glioma cells inhibits Akt activation and induces anoikis. <i>Cancer Research</i> , 1998, 58, 5285-90.	0.9	160